Form 4: CME Group Director Charles P. Carey Sells Over $132K in Company Stock Under Pre-Arranged Plan

CME Group Inc. Director Charles P. Carey reported the sale of 500 shares of Class A Common Stock for approximately $132,676.50 on June 10, 2025, as part of a Rule 10b5-1 plan.

Summary

• CME Group Inc. Director Charles P. Carey sold a total of 500 shares of the company's Class A Common Stock on June 10, 2025.
• The sales occurred in two separate direct transactions: 150 shares at $265.36 per share and 350 shares at $265.35 per share.
• The total value of the shares sold amounts to approximately $132,676.50.
• These transactions were conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Mr. Carey's indirect beneficial ownership includes 5,250 shares held by a Trust, 4,900 shares held by another Trust, 185 shares held by a Firm, and 0.375 shares held by a Partnership.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports a routine insider stock sale by a director. While insider sales can sometimes be viewed negatively, the transaction was conducted under a pre-arranged 10b5-1 plan, which suggests it was not based on new, adverse material information.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating a pre-scheduled sale rather than a discretionary one based on new, non-public information.

Negatives

• A director, Charles P. Carey, sold 500 shares of company stock, which, despite being pre-planned, represents a reduction in insider holdings.

Risks

• Insider selling, even when pre-planned under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially leading to short-term price pressure or questions about insider confidence.

Future Outlook

NA

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape for CME Group Inc.

Stakeholder Impact

• Shareholders: May observe the director's sale, but the impact is likely minimal given the transaction's pre-planned nature and the relatively small volume compared to CME Group's overall market capitalization.

Key Dates

Recommendation

Keywords

CME Group, CME, Insider Trading, Form 4, Stock Sale, Director, Charles P. Carey, Beneficial Ownership, SEC Filing, Equity Transaction, 10b5-1 Plan